Merck announced the Board of Directors has declared a quarterly dividend of $0.47 per share of the company’s common stock for the fourth quarter of 2017. Payment will be made on Oct. 6, 2017 to shareholders of record at the close of business on Sept. 15, 2017.
Merck has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Through prescription medicines, vaccines, biologic therapies and animal health products, the company works with customers and operate in more than 140 countries to deliver health solutions. Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola.